{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"EP Edge Journal Watch: Cardiac Electrophysiology Research","title":"Pulsed Field Ablation, Atrial Fibrillation Progression & Leadless Pacing | EP Edge Journal Watch – Jan 2026 (Issue 5)","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/2f092ade\"></iframe>","width":"100%","height":180,"duration":2033,"description":"EP Edge Journal Watch — January 2026 | Issue #5\nPulsed Field Ablation, Device Therapy, and the Era of Personalized EP\nWelcome to EP Edge Journal Watch – Issue #5 (January 2026), your high-yield, evidence-driven electrophysiology podcast designed for practicing EPs who want more than just abstracts.\nAs 2026 begins, electrophysiology is entering a defining phase—where pulsed field ablation (PFA) matures beyond feasibility, device therapy is reframed by competing risk, and “one-size-fits-all” ablation strategies give way to personalization.\nIn this episode, Dr. Niraj Sharma MD FACC FHRS breaks down practice-changing trials, real-world registries, and mechanistic insights that are actively reshaping how we approach atrial fibrillation ablation, ICD decision-making, leadless pacing, and AF progression.\nWhat’s covered in this issue:\nLong-term ICD outcomes in nonischemic cardiomyopathy\nWhy preventing sudden death does not always translate into survival benefit—and how age and competing risk matter.\nLeadless pacing evolution\nDual-chamber leadless pacemakers, operator learning curves, and why high acute atrial thresholds don’t predict chronic failure.\nReducing CIED infections\nHow a simple iodinated adhesive drape significantly lowers contamination and infection risk.\nAF progression as a biologic signal\nWhy device-detected AF progression predicts mortality, heart failure, and stroke risk.\nMonitoring-driven AF management\nHow implantable cardiac monitors change rhythm-control strategies and outcomes.\nPulsed Field Ablation at scale\nCE-Mark data, IDE trials, and the MANIFEST-US registry defining safety, durability, and workflow in real-world PFA.\nRare but serious delayed PFA complications\nWhat every electrophysiologist should know about delayed ischemia and malignant arrhythmias.\nPersonalized AF ablation strategies\nLA wall thickness–guided ablation, sex-specific outcomes, and patient-factor–driven lesion optimization beyond PVI-only.\nWhy this episode matters:\nThis is not...","thumbnail_url":"https://img.transistorcdn.com/C7iPWVsHlGRm13syn3X4eXGLcqOXyzcuH5XmVutqgHc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jMzFi/ZTYxOTI1M2U4NGRj/OGZmZjBhMDFlMjFm/NDQwMC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}